MiMedx Receives FDA Warning Letter On Axiofill Production
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – MiMedx Group Inc. (MDXG) announced receipt of a warning letter from the United States Food and Drug Administration regarding Axiofill Classification. Meanwhile, the company reiterated its outlook for 2023 full year net sales growth and fourth quarter adjusted EBITDA m
:max_bytes(150000):strip_icc():format(jpeg)/business-team-investment-entrepreneur-trading-discussing-and-analysis-graph-stock-market-trading-stock-chart-concept-1089940388-acef8549576a4d918cb157c6c88ec8a1.jpg "Introduction to Phantom Stocks and SARs")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-991180154-aad62bea33e2473a808a24eb81b8e068.jpg "How the Minimum Wage Impacts Unemployment")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1427847593-c401663a1b954137ac712a650eea3a95.jpg "Borrowing from Your Retirement Plan")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1711953018-c9f8489969fb4eb5b4108181d0d42071.jpg "Are We in a Baby Boomer Retirement Crisis?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1889646212-29894e7d25f24600ab15c966a1c78f89.jpg "The Long, Weird History of Universal Basic Income—and Why It’s Back")